Abstract
Purpose of Review: This review highlights select studies presented at the virtual 2021 European Society of Cardiology (ESC) Congress. Recent Findings: Reviewed studies assess single photon emission computed tomography, positron emission tomography, magnetic resonance imaging in coronary artery disease (PACIFIC-II); empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); dapagliflozin in chronic heart failure (DAPA-HF); proprotein convertase subtilisin/kexin type 9 inhibitor and its lipid lowering effects (NATURE-PCSK9); fixed-dose combination therapies with or without aspirin in primary prevention; overview of contrasting results between REDUCE-IT versus STRENGTH trials; Quadruple UltrA-low-dose tReaTment for hypertension (QUARTET); evolocumab and changes in plaque composition on optical coherence tomography (HUYGENS); and low-dose rivaroxaban during the acute phase of acute coronary syndrome (H-REPLACE). Summary: Research presented at the 2021 ESC Congress shows promise in reducing burden of cardiovascular disease and reinforces the value of cardiovascular disease prevention.
Original language | English |
---|---|
Article number | 76 |
Journal | Current Atherosclerosis Reports |
Volume | 23 |
Issue number | 12 |
DOIs | |
Publication status | Published - Dec 2021 |
Externally published | Yes |
Keywords
- Aspirin
- Atherosclerotic cardiovascular disease
- Cardiovascular prevention
- Dapagliflozin
- Empagliflozin
- Heart failure